Outbreak of measles at a vocational training school

A measles outbreak which started in the technical institute Els Ports in Albocacer (Castellón), and involved nearby towns was studied. The outbreak was described using a retrospective cohort study to estimate the efficacy of the antimeasles vaccination (EV) by a questionnaire distributed in the inst...

Full description

Saved in:
Bibliographic Details
Published inEnfermedades infecciosas y microbiología clínica Vol. 12; no. 3; p. 127
Main Authors Arnedo, A, Bellido, J, Vidal, J, Peñarrocha, J, Cortés, A, González, F, Momparler, P, Pac, M R, Calvo, C, Safont, L
Format Journal Article
LanguageSpanish
Published Spain 01.03.1994
Subjects
Online AccessGet more information

Cover

Loading…
More Information
Summary:A measles outbreak which started in the technical institute Els Ports in Albocacer (Castellón), and involved nearby towns was studied. The outbreak was described using a retrospective cohort study to estimate the efficacy of the antimeasles vaccination (EV) by a questionnaire distributed in the institute. Response rate was 80.7%. A clinical definition of measles was used with EV being calculated by 2 different formulas. Antimeasles vaccination coverage (VC) in primary schools of the towns involved was also assessed. The outbreak occurred from February to April 1992, including 13 cases of measles (mean age: 13.6 +/- 2.7 years). Eleven patients (84.6%) had not been vaccinated. The attack rate the above mentioned institute was 9.1% (8 cases/88 students) with VC of 40.9%. An association was found only between being vaccinated and not having measles, relative risk 0.07 (confidence limits [CL] 95%: 0.01-0.50). EV was 92.9% (CL 95%: 50-99%) using the traditional formula and 96.2% (CL 95%: 88.2-100%) using the new formula. The VC in the schools was 92.3%. Vaccination with the triple viral vaccine was recommended to susceptible individuals. Despite specific vaccination measles continues to produce epidemics. A second dose of the triple viral vaccine is recommended for being included in the vaccination calendar between the age of 6 and 14 years.
ISSN:0213-005X